Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Post by TheHoboon Mar 19, 2010 2:57pm

301 Views

Post# 16904183

Relax

This is from the AGASP site translated, the last paragraph which is important:

The director general ofthe National Department of Mineral Production (DNPM), Miguel AntonioCedraz Nery, told the hearing's public picaretagem that we are convincedthat the choice of Coomigasp and business partner to play thedevelopment of Serra Pelada was the technical solution more appropriate. Secretary of Geology,Mining and Mineral Processing of the Ministry of Mines and Energy,Claudio Scliar said the EMA will not be involved in the internal affairsof the cooperative and that the mining license will be delivered byPresident Lula this month.

Bullboard Posts

Hempalta acquires controlling interest in Hemp Carbon Standard